JP2022516006A5 - - Google Patents
Info
- Publication number
- JP2022516006A5 JP2022516006A5 JP2021535833A JP2021535833A JP2022516006A5 JP 2022516006 A5 JP2022516006 A5 JP 2022516006A5 JP 2021535833 A JP2021535833 A JP 2021535833A JP 2021535833 A JP2021535833 A JP 2021535833A JP 2022516006 A5 JP2022516006 A5 JP 2022516006A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleotide sequence
- promoter
- nucleic acid
- vaccinia virus
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862784372P | 2018-12-21 | 2018-12-21 | |
| US62/784,372 | 2018-12-21 | ||
| US201962872699P | 2019-07-10 | 2019-07-10 | |
| US62/872,699 | 2019-07-10 | ||
| US201962930524P | 2019-11-04 | 2019-11-04 | |
| US62/930,524 | 2019-11-04 | ||
| PCT/CA2019/051899 WO2020124274A1 (en) | 2018-12-21 | 2019-12-20 | Modified orthopoxvirus vectors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022516006A JP2022516006A (ja) | 2022-02-24 |
| JP2022516006A5 true JP2022516006A5 (enExample) | 2023-01-04 |
Family
ID=71100021
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021535804A Pending JP2022514420A (ja) | 2018-12-21 | 2019-12-20 | 修飾オルソポックスウイルスベクター |
| JP2021535833A Pending JP2022516006A (ja) | 2018-12-21 | 2019-12-20 | 修飾オルソポックスウイルスベクター |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021535804A Pending JP2022514420A (ja) | 2018-12-21 | 2019-12-20 | 修飾オルソポックスウイルスベクター |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US20220056480A1 (enExample) |
| EP (2) | EP3898997A4 (enExample) |
| JP (2) | JP2022514420A (enExample) |
| KR (2) | KR20210132003A (enExample) |
| CN (2) | CN113661246A (enExample) |
| AU (2) | AU2019404639A1 (enExample) |
| BR (2) | BR112021012078A2 (enExample) |
| CA (2) | CA3124301A1 (enExample) |
| CL (1) | CL2021001646A1 (enExample) |
| CO (1) | CO2021009354A2 (enExample) |
| EC (1) | ECSP21053474A (enExample) |
| IL (2) | IL284180A (enExample) |
| MX (2) | MX2021007438A (enExample) |
| PE (1) | PE20212307A1 (enExample) |
| PH (1) | PH12021551436A1 (enExample) |
| SG (1) | SG11202106460XA (enExample) |
| TW (1) | TW202039851A (enExample) |
| WO (2) | WO2020124273A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10612005B2 (en) | 2016-01-08 | 2020-04-07 | Replimune Limited | Modified oncolytic virus |
| JP7724601B2 (ja) | 2017-02-03 | 2025-08-18 | ユニバーシティ オブ ピッツバーグ －オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション | 腫瘍溶解性ウイルス療法 |
| SG11202006457YA (en) | 2018-01-05 | 2020-08-28 | Ottawa Hospital Res Inst | Modified orthopoxvirus vectors |
| EP4061417A4 (en) * | 2019-11-20 | 2023-10-11 | University of Pittsburgh - of the Commonwealth System of Higher Education | VACCINIA VIRUSES AND METHOD FOR USING VACCINIA VIRUSES |
| JP6915792B1 (ja) * | 2020-10-01 | 2021-08-04 | 国立大学法人鳥取大学 | 広範囲遺伝子欠損を有する腫瘍溶解性ワクシニアウイルス |
| WO2023106839A1 (ko) * | 2021-12-07 | 2023-06-15 | 재단법인 아산사회복지재단 | Il-12를 발현하는 재조합 백시니아 바이러스 및 이의 용도 |
| JP2025503721A (ja) * | 2022-01-17 | 2025-02-04 | ノイスコム アーゲー | がん治療用免疫刺激タンパク質をコードする組換えオルソポックスウイルスベクター |
| CN119677861A (zh) * | 2022-06-10 | 2025-03-21 | 特兰斯吉恩股份有限公司 | 表达白介素-12的重组病毒 |
| IL318055A (en) * | 2022-07-08 | 2025-02-01 | Viromissile Inc | ONCOLYTIC VACCINIA VIRUSES AND RECOMBINANT VIRUSES AND METHODS OF USE THEREOF |
| CN119923267A (zh) * | 2022-07-27 | 2025-05-02 | 阿斯利康(瑞典)有限公司 | 表达白介素-12的重组病毒与pd-1/pd-l1抑制剂的组合 |
| CN115947797B (zh) * | 2022-08-02 | 2024-07-05 | 青岛硕景生物科技有限公司 | 猴痘病毒重组抗原及其应用 |
| WO2024130212A1 (en) | 2022-12-16 | 2024-06-20 | Turnstone Biologics Corp. | Recombinant vaccinia virus encoding one or more natural killer cell and t lymphocyte inhibitors |
| CN116200349A (zh) * | 2023-01-18 | 2023-06-02 | 中国医学科学院病原生物学研究所 | 一种基于改良痘苗病毒天坛株的新型冠状病毒疫苗 |
| CN115927215B (zh) * | 2023-01-18 | 2025-10-17 | 中国医学科学院病原生物学研究所 | 一种定向减毒的痘苗病毒疫苗 |
| CN118240879A (zh) * | 2023-11-01 | 2024-06-25 | 上海市重大传染病和生物安全研究院 | 骨架质粒、重组质粒以及猴痘病毒颗粒和应用 |
| WO2026047314A1 (en) * | 2024-08-28 | 2026-03-05 | University Of Surrey | Recombinant vector |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2150495T5 (es) * | 1993-05-19 | 2007-02-16 | Schering Corporation | Ligandos de flt3 purificados de mamifero y agonistas y antagonistas de los mismos. |
| KR20120002613A (ko) * | 2002-08-12 | 2012-01-06 | 제네렉스, 인코포레이티드 | 폭스바이러스 및 암과 관련된 방법 및 조성물 |
| AU2003290528A1 (en) * | 2002-10-15 | 2004-05-04 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Methods and reagents for inducing immunity |
| RU2503717C2 (ru) * | 2007-11-19 | 2014-01-10 | Трансжене Са | Поксвирусные онколитические векторы |
| RS65104B1 (sr) * | 2013-08-22 | 2024-02-29 | Univ Pittsburgh Commonwealth Sys Higher Education | Onkolitičke imunoterapije |
| RU2696312C2 (ru) * | 2014-07-16 | 2019-08-01 | Трансген Са | Онколитический вирус для экспрессии модуляторов иммунологических контрольных точек |
| CN106520778A (zh) * | 2015-09-09 | 2017-03-22 | 北京锤特生物科技有限公司 | 改造的白介素12及其在制备治疗肿瘤的药物中的用途 |
| WO2018049248A1 (en) * | 2016-09-09 | 2018-03-15 | Icellhealth Consulting Llc | Oncolytic virus equipped with bispecific engager molecules |
| SG11202006457YA (en) * | 2018-01-05 | 2020-08-28 | Ottawa Hospital Res Inst | Modified orthopoxvirus vectors |
-
2019
- 2019-12-20 EP EP19898487.4A patent/EP3898997A4/en not_active Withdrawn
- 2019-12-20 TW TW108147116A patent/TW202039851A/zh unknown
- 2019-12-20 AU AU2019404639A patent/AU2019404639A1/en not_active Abandoned
- 2019-12-20 KR KR1020217022872A patent/KR20210132003A/ko not_active Ceased
- 2019-12-20 MX MX2021007438A patent/MX2021007438A/es unknown
- 2019-12-20 CN CN201980092788.4A patent/CN113661246A/zh active Pending
- 2019-12-20 CN CN201980091966.1A patent/CN113454231A/zh active Pending
- 2019-12-20 WO PCT/CA2019/051898 patent/WO2020124273A1/en not_active Ceased
- 2019-12-20 EP EP19899693.6A patent/EP3898998A4/en not_active Withdrawn
- 2019-12-20 BR BR112021012078-5A patent/BR112021012078A2/pt not_active Application Discontinuation
- 2019-12-20 JP JP2021535804A patent/JP2022514420A/ja active Pending
- 2019-12-20 CA CA3124301A patent/CA3124301A1/en active Pending
- 2019-12-20 JP JP2021535833A patent/JP2022516006A/ja active Pending
- 2019-12-20 PE PE2021000922A patent/PE20212307A1/es unknown
- 2019-12-20 AU AU2019410148A patent/AU2019410148A1/en not_active Abandoned
- 2019-12-20 BR BR112021011730-0A patent/BR112021011730A2/pt not_active Application Discontinuation
- 2019-12-20 WO PCT/CA2019/051899 patent/WO2020124274A1/en not_active Ceased
- 2019-12-20 US US17/415,575 patent/US20220056480A1/en not_active Abandoned
- 2019-12-20 US US17/415,606 patent/US20220380799A1/en not_active Abandoned
- 2019-12-20 SG SG11202106460XA patent/SG11202106460XA/en unknown
- 2019-12-20 KR KR1020217022871A patent/KR20210132002A/ko not_active Ceased
- 2019-12-20 MX MX2021007439A patent/MX2021007439A/es unknown
- 2019-12-20 CA CA3124287A patent/CA3124287A1/en active Pending
-
2021
- 2021-06-17 PH PH12021551436A patent/PH12021551436A1/en unknown
- 2021-06-18 CL CL2021001646A patent/CL2021001646A1/es unknown
- 2021-06-19 IL IL284180A patent/IL284180A/en unknown
- 2021-06-20 IL IL284188A patent/IL284188A/en unknown
- 2021-07-16 CO CONC2021/0009354A patent/CO2021009354A2/es unknown
- 2021-07-20 EC ECSENADI202153474A patent/ECSP21053474A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022516006A5 (enExample) | ||
| JP2022514420A5 (enExample) | ||
| JP7336457B2 (ja) | 抗体Ｆｃ領域を主鎖として用いた融合タンパク質二量体及びその使用 | |
| US10660947B2 (en) | Vaccine composition | |
| AU2025267444A1 (en) | Chimeric antigen receptor t cells (car-t) for the treatment of cancer | |
| ES2359473T3 (es) | Citoquinas multifuncionales. | |
| DK2986311T3 (en) | IMPROVED ADOPTIVE CELL THERAPY | |
| US11795203B2 (en) | Protein heterodimer and use thereof | |
| CN104870477B (zh) | Gm-csf和il-4轭合物、组合物以及与其相关的方法 | |
| JP7679303B2 (ja) | がんを治療するための腫瘍溶解性ウイルスの使用 | |
| ES2926227T3 (es) | Receptor de antígeno quimérico con dominio de activación o bloqueo del receptor de citoquinas | |
| JPH09502993A (ja) | 免疫または炎症応答の調節による抗がん遺伝子療法 | |
| JP7340222B2 (ja) | 腫瘍溶解性ウイルス、腫瘍溶解性ウイルスを含む薬物、医薬品の製造における使用、および腫瘍溶解性ウイルスの作製方法 | |
| KR20230150834A (ko) | Ap-1 전사 인자를 인코딩하는 코돈-최적화된 뉴클레오티드 서열 | |
| WO2019080537A1 (zh) | 包含溶瘤病毒和car-nk细胞的治疗剂及应用、药盒、治疗肿瘤和/或癌症的方法 | |
| US20190151437A1 (en) | Combination prime: boost therapy | |
| CN110325207A (zh) | 武装溶瘤病毒 | |
| JP2024510712A (ja) | Ｉｌ－１５をコードするアデノウイルス | |
| WO2019151759A1 (ko) | 신규 백신 면역보조제 | |
| CN118900697A (zh) | 使用白细胞介素减轻双特异性t细胞接合器或嵌合抗原受体t细胞介导的细胞因子释放综合征的方法 | |
| CN117203342A (zh) | 人乳头瘤病毒疫苗及其用于hpv相关疾病的用途 | |
| US20260078349A1 (en) | Enhanced adoptive cell therapy | |
| US12233135B2 (en) | Therapeutic constructs for treating cancer | |
| US20250115657A1 (en) | Bispecific FC Fusion Proteins with sPD-1 and IL-15 | |
| CN114364390A (zh) | 用于治疗癌症的包含抗癌病毒、免疫检查点抑制剂和羟基脲作为活性成分的药物组合物 |